Device Trial Radar · NCT06042205
TISSIUM™ Atraumatic Hernia Repair System (TAHRS) Pilot Study
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Jul 4, 2023
Primary completion
Jul 4, 2026
Study completion Oct 30, 2026
Sponsor
- Lead sponsor
- TissiumNot on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 18, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to capture preliminary clinical safety and performance on the TAHRS
Conditions
- Hernia
Interventions
TISSIUM™ Atraumatic Hernia Repair System (TAHRS)Device
The TAHRS is intended for fixation of prosthetic material to soft tissue
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serious Adverse Device Effect (SADEs)Time frame: through 12 months post-surgery
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Imelda Hospital
Bonheiden, Belgium
AZ Sint-Jan
Ruddershove, Belgium
CHU UCL Namur
Yvoir, Belgium
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.